Skip to main content
NCBI home page
Biophysical Journal logoLink to Biophysical Journal
. 1996 Oct;71(4):1672–1679. doi: 10.1016/S0006-3495(96)79411-0

In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy.

L P Choo 1, D L Wetzel 1, W C Halliday 1, M Jackson 1, S M LeVine 1, H H Mantsch 1
PMCID: PMC1233637  PMID: 8889145

Abstract

We report the first evidence of the structure of beta-amyloid protein as it exists in situ within a slice of human Alzheimer's diseased brain tissue. Using a Fourier transform infrared microspectroscopic technique, areas of interest can be selected for spectral measurements with regions of potential contamination masked. In so doing, it is possible to obtain infrared spectra only of beta-amyloid and not the surrounding grey matter within which it lies. However, to obtain spectra of high-quality signal-to-noise ratio using a conventional infrared source, we were limited to aperture sizes between 24 microns x 24 microns to 50 microns x 50 microns. Markedly improved high-quality spectra were acquired with infrared radiation provided by a synchrotron light source (National Synchrotron Light Source, Brookhaven National Laboratories), using aperture sizes as small as 12 microns x 12 microns. This allowed spectroscopic mapping of brain tissue regions containing amyloid. We observe that in situ protein of grey matter exist predominantly in an alpha-helical and/or unordered conformation, whereas within amyloid deposits a beta-sheet structure predominates. The hydrogen bonding strength of the beta-structure found in situ is different from that reported in the literature for isolated/chemically synthesized beta-amyloid peptides.

Full text

PDF
1672

Images in this article

1675FIGURE 3
on p.1675
1676FIGURE 4
on p.1676
1677FIGURE 6
on p.1677
1677FIGURE 7
on p.1677

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrow C. J., Zagorski M. G. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science. 1991 Jul 12;253(5016):179–182. doi: 10.1126/science.1853202. [DOI] [PubMed] [Google Scholar]
  2. Choo L. P., Jackson M., Halliday W. C., Mantsch H. H. Infrared spectroscopic characterisation of multiple sclerosis plaques in the human central nervous system. Biochim Biophys Acta. 1993 Oct 20;1182(3):333–337. doi: 10.1016/0925-4439(93)90078-f. [DOI] [PubMed] [Google Scholar]
  3. Fabian H., Szendrei G. I., Mantsch H. H., Greenberg B. D., Otvös L., Jr Synthetic post-translationally modified human A beta peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. Eur J Biochem. 1994 May 1;221(3):959–964. doi: 10.1111/j.1432-1033.1994.tb18811.x. [DOI] [PubMed] [Google Scholar]
  4. Fraser P. E., Lévesque L., McLachlan D. R. Biochemistry of Alzheimer's disease amyloid plaques. Clin Biochem. 1993 Oct;26(5):339–349. doi: 10.1016/0009-9120(93)90110-r. [DOI] [PubMed] [Google Scholar]
  5. Fraser P. E., McLachlan D. R., Surewicz W. K., Mizzen C. A., Snow A. D., Nguyen J. T., Kirschner D. A. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. J Mol Biol. 1994 Nov 18;244(1):64–73. doi: 10.1006/jmbi.1994.1704. [DOI] [PubMed] [Google Scholar]
  6. Fraser P. E., Nguyen J. T., Inouye H., Surewicz W. K., Selkoe D. J., Podlisny M. B., Kirschner D. A. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry. 1992 Nov 10;31(44):10716–10723. doi: 10.1021/bi00159a011. [DOI] [PubMed] [Google Scholar]
  7. Fraser P. E., Nguyen J. T., Surewicz W. K., Kirschner D. A. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J. 1991 Nov;60(5):1190–1201. doi: 10.1016/S0006-3495(91)82154-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Inouye H., Fraser P. E., Kirschner D. A. Structure of beta-crystallite assemblies formed by Alzheimer beta-amyloid protein analogues: analysis by x-ray diffraction. Biophys J. 1993 Feb;64(2):502–519. doi: 10.1016/S0006-3495(93)81393-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jackson M., Mantsch H. H. The use and misuse of FTIR spectroscopy in the determination of protein structure. Crit Rev Biochem Mol Biol. 1995;30(2):95–120. doi: 10.3109/10409239509085140. [DOI] [PubMed] [Google Scholar]
  10. Jafek B. W., Hill D. P. Surgical management of chemosensory disorders. Ear Nose Throat J. 1989 May;68(5):398, 400, 402-4. [PubMed] [Google Scholar]
  11. Jarrett J. T., Berger E. P., Lansbury P. T., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11;32(18):4693–4697. doi: 10.1021/bi00069a001. [DOI] [PubMed] [Google Scholar]
  12. Katzman R., Jackson J. E. Alzheimer disease: basic and clinical advances. J Am Geriatr Soc. 1991 May;39(5):516–525. doi: 10.1111/j.1532-5415.1991.tb02500.x. [DOI] [PubMed] [Google Scholar]
  13. Khachaturian Z. S. Diagnosis of Alzheimer's disease. Arch Neurol. 1985 Nov;42(11):1097–1105. doi: 10.1001/archneur.1985.04060100083029. [DOI] [PubMed] [Google Scholar]
  14. Maury C. P. Molecular pathogenesis of beta-amyloidosis in Alzheimer's disease and other cerebral amyloidoses. Lab Invest. 1995 Jan;72(1):4–16. [PubMed] [Google Scholar]
  15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  16. Mirra S. S., Hart M. N., Terry R. D. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med. 1993 Feb;117(2):132–144. [PubMed] [Google Scholar]
  17. Otvos L., Jr, Szendrei G. I., Lee V. M., Mantsch H. H. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. Eur J Biochem. 1993 Jan 15;211(1-2):249–257. doi: 10.1111/j.1432-1033.1993.tb19893.x. [DOI] [PubMed] [Google Scholar]
  18. Selkoe D. J. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994 Sep;53(5):438–447. doi: 10.1097/00005072-199409000-00003. [DOI] [PubMed] [Google Scholar]
  19. Sisodia S. S., Price D. L. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 1995 Mar;9(5):366–370. doi: 10.1096/fasebj.9.5.7896005. [DOI] [PubMed] [Google Scholar]
  20. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977–1981. doi: 10.1073/pnas.90.5.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., Neve R. L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989 Jul 28;245(4916):417–420. doi: 10.1126/science.2474201. [DOI] [PubMed] [Google Scholar]
  22. Zagorski M. G., Barrow C. J. NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix----beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry. 1992 Jun 23;31(24):5621–5631. doi: 10.1021/bi00139a028. [DOI] [PubMed] [Google Scholar]

Articles from Biophysical Journal are provided here courtesy of The Biophysical Society

RESOURCES